Genmab — November 2017
-
In the Netherlands, the National Health Care Institute determines and advises on which types of health care are included in the basic care package and which are not. There was an advisory committee meeting oktober 27 on daratumumab. This was an open meeting, but only today they published their advice to their board: (in dutch) https://www.zorginstituutnederland.nl/publicaties/adviezen/2017/10/27/advies-acp-aan-de-rvb-over-de-beoordeling-van-daratumumab-darzalex-bij-multipel-myeloom
-
-
-
This what could
happen in the US if Bernie Sanders become their next president! Bye bye peak sale estimates! -
-
Going Dutch is acceptable (but IMO not gallant) going on a date, but going dutch on health care with the suppliers seems odd. When they then ask the business to have a greater heart than the State and provide it for compassionate use, I would consider stop paying my taxes.
-
had to smile here, it reads "We thank AbbVie, Celgene, Takeda and Amgen for their support" and then the guy says: "Dara clearly is going to have a potential role in maintenance setting in the future " wrong sponsor mate
https://www.patientpower.info/video/ask-the-expert-any-updates-on-the-use-of-the-new-immuno-drugs-for-maintenance-in-myeloma -
meanwhile HollandBio promoting itself at BIO Europe with the cheapest box they could find
https://twitter.com/HollandBIO/status/927880167099392000
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind